Potential of preventing pseudomonas aeruginosa lung infections in cystic flbrosis patients: Experimental studies in animals

APMIS, Supplement

Volumn 104, Issue 63, 1996, Pages 5-42

  Johansen, Helle Krogh ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; CYSTIC FIBROSIS; DISEASE MODEL; GRAM NEGATIVE INFECTION; HUMAN; MICROBIOLOGY; REVIEW; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONTROLLED STUDY; HYPERSENSITIVITY REACTION; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG INFECTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

ANIMALS; CYSTIC FIBROSIS; DISEASE MODELS, ANIMAL; HUMANS; PSEUDOMONAS INFECTIONS;

CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; VACCINE;

EID: 0030340458     PISSN: 0903465X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (311)

1. Abman, S. H., Ogle, J. W., Butler-Simon, N., Rumack. C. M. & Accurso, F. J.: Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J. Pediatr. 113: 827830,1988.
2. Abman, S. H., Ogle, J. W, Harbeck, R. J., Biitkrsimon, N., Hammond, K. B. & Accurso, F. J.: Early bacteriologie, immunologie, and clinical courses ofyoung infants with cystic fibrosis identified by neonatal screening. J. Pediatr. 119:211-217,1991.
3. Adams, D. H. & Sliamt, S.: Leukocyte-endothelial interactions and regulation of leukocyte migration. Lancet 343: 831-836,1994.
4. Al-Jader. L. N., Meredith, A. L., Reyley, H. C, Cheadle, J. P., Maguire, S., Owen, G., Goodchild. M. C. & Harper, P. S.: Severity of chest disease in cystic fibrosis patients in relation to their genotypes. J. Med. Genet. 29:883-887, 1992.
5. Allison, A. C. & Byars, N. R: Adjuvants for a new generation of vaccines. In: Woodrow G. C. & Levine, M. M. (Eds.): New generation vaccines. Marcel Decker, New York 1990, pp. 129-140.
6. Allison, A. C. & Byars, N. E. : Immunological adjuvants. In: CiardiJ. E, McGliec, J. R. & Keith. J. M. (Eds.): Genetically engineered vaccines. Plenum Press, New York-London 1992, vol. 327, pp. 133-141.
7. Alton, K W. F. W, Middleton, P. G., Caplen, N. J., Smith, S. N., Steel, D. M., Munkonge, F. M., Jeffery, P. K., Geddes, D. M., Hart, S. L.,\Villiamson, R., Fasold, K. L, Miller, A. D., Dickinson, P., Stevenson, B. J., McLachlan, G., Darin, J. R. & Porteous, D. J.: Non-invasive liposomemediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nature Genetics 5:135-142,1993.
8. Andersen, D. H.: Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study. Am. J. Dis. Child. 56:344-399,1938.
9. Amvar, H., Dasgupta, M., Lam, K. & Costerton, J. Fff.Tobramycin resistance of mucoid Pseiidomonas aeruginosa biofilm grown under iron limitation. J. Antimicrob. . Chemother. 24:647-655,1989.
10. Aoi, Y, Noda, H., Yanagawa, R., Homma, J. Y, Abe, C, Morihara, K., Goda, A., Takeuchi, S. & Ishihara, T.: Protection against haemorrhagic pneumonia of mink by Pseiidomonas aentginosa multicomponent vaccine. Jap. J. Exp. Med.49:199-207,1979.
11. Aiidibert, F. M. & Lise, L. D.: Adjuvants: current status, clinical perspectives and future prospects. Immunol. Today 74:281-284,1993.
12. Auerbach, H. S., Kirkpatrick, J. A., Williams, M. & Colten, H. R. : Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 686-688,1985.
13. Baggiolini, M., Walz, A. & Kunkel, S. L : Neutrophil-activation peptide-l/interleukin-8, a novel cytokine that activates neutrophils. J. Clin. Invest. 84:1045-49,1989.
14. Baker, N. R., Minor, V, Deal, C., Shahrabadi, M. S., Simpson, D. A. & Woods, D. E.: Pseiidomonas aeruginosa exoenzyme S is an adhesin. Infect. Immun. 59:28592863,1991.
15. Baltimore, R. S., Christie, C. D. C. & Smith, G. J. W: Im-munohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis: implications for the pathogenesis of progressive lung deterioration. Am. Rev. Respir. Dis. 140: 1650-1661, 1989.
16. Bear, C. R, Li, C, Kartner, N., Bridges, R. J., Jemen, T. J., Ramjeesingh, M. & Riordan, J. R.: Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 68: 809-818,1992.
17. Berger, At.: Inflammation in the lung in cystic fibrosis: a vicious cycle that does more harm than good. Clin. Rev. Allergy 9:119-142,1991.
18. Bisgaard, H., Nielsen, K. G., Skov, M., Mosfeldt, R, Bjerre, B., Pedersen, S. S., Hoiby, N. C.: Inhaled steroid treatment of CF patients with chronic Pseudomonas aeruginosa lung infection. Pediatr. Pulmonol. Suppl. 9:289,1994.
19. Blackwood, L. L. & Pennington, J. R: Influence of mucoid coating on clearance of Pseudomonas aeruginosa from lungs. Infect. Immun. 52:443-448,1981.
20. Blackwood, L. L, Stone, R. M., Iglewski, B. H. & Pennington, J. R: Evaluation of Pseudomonas aeruginosa exotoxin A and elastase as virulence factors in acute lung infection. Infect. Immun. 39:198-201,1983.
21. Boat, T. K, Welsh, M.J. & Beaudet, A. L. : Cystic Fibrosis. In: Scriver C. R., Beaudet, A. L, Sly, W. S. & Volle, D. (Eds.): The metabolic basis of inherited disease. McGraw-Hill, New York 1989, pp. 2649-2680.
22. Bomford. R.. Stapleton, M. & Winsor, S.: Immunomodulation by adjuvants. In: Gregoriadis G., Allison, A. C. & Poste, G. (Eds.): Vaccines: recent trends and progress. Plenum Press, New York-London 1991, vol. 275, pp. 2532.
23. Botzenhart, K. & Daring, G.: Ecology and epidemiology of Pseudomonas aeruginosa. In: Campa M., Bendinelli, M. & Friedman, H. (Eds.): Pseudomonas aeruginosa as an opportunistic pathogen. Plenum Press, New York 1993, pp. 1-18.
24. Boyd, R. L., Ramphal, R., Rice, R. & Mangos, J. A.: Chronic colonization of rat airways with Pseudomonas aeruginosa. Infect. Immun. 39:1403-1410,1983.
25. Brandt, N. J., Schn-artz, M. & Skovby, F.: Screening for carriers of cystic fibrosis. A pilot study among pregnant women. Ugeskr. Lceger756:3751-3757,1994.
26. Brandtzaeg, P.: Humoral immune response patterns of human mucosae: induction and relation to bacterial respiratory tract infections. J. Infect. Dis. 755: S167-S176, 1992.
27. Brandtzaeg, P.: Molecular and cellular aspects of the secretory immunoglobulin system. APMIS 103: 1-19, 1995.
28. Brett, M. M., Ghoneim, A. T. M. & Littlewood, J. M.: Serum IgA antibodies against Pseudomonas aeruginosa in cystic fibrosis. Arch. Dis. Child. 65:259-263,1990.
29. Bruderer, U., Cryz Jr.,S.J., Schaad, U. B., Deusinger, M., Que, J.U.& Lang, A. B.: Affinity constants of naturally acquired and vaccine-induced anti-Psettdomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients. J. Infect. Dis. 766:344-349,1992.
30. Bruderer, U.. Fürer, K, Cryz Jr., S. J. & Lang, A. B.: Properties determining the potential of naturally occurring and vaccine-induced human antibodies to protect against lethal infection of Pseudomonas aeruginosa. Res. Immunol. 143:165-174, 1992.
31. Buret, A. & Cripps, A. W.:The immunoevasive activities ofPseudomonas aeruginosa. Am. Rev. Respir. Dis. 148: 793-805,1993.
32. Buret, A., Dunkley. M., Clancy, R.L.& Cripps, A. W.:Effector mechanisms of intestinally induced immunity to Pseudomonas aeruginosa in the rat lung: role of neutrophils and leukotriene 64. Infect. Immun. 61: 671-679, 1993.
33. Buret, A., Dunkley, M. L, Clancy. R.L. & Cripps, A. W: Pulmonary immunity to Pseudomonas aeruginosa in intestinally immunized rats: roles of alveolar macrophages, tumour necrosis factor a, and interleukin-1α. Infect. Immun. 62:5335-5343,1994.
34. Cain, T.K. & Rank, R. G. : Local Thl-like responses are induced by intravaginal infection of mice with the mouse pneumonitis biovar of Chlamydia trachomatis. Infect. Immun. 63:1784-1789, 1995.
35. Cash, H. A., Straus, D. C. & Bass, J. A.: Pseudomonas aeruginosa exoproducts as pulmonary virulence factors. Can. J. Microbiol. 29: 448-456,1983.
36. Cash, H. A., Woods, D. K, McCtillotigh, B., Johanson Jr., W.G. & Bass, J. A.: A rat model of chronic respiratory infection with Pseudomonas aeruginosa. Am. Rev. Respir. Dis. 779:453-459,1979.
37. Cheting, A. T. W. Moss, R. B.. Kurland. G.. Leong, A. B. & Novick, W J.: Chronic Pseudomonas aeruginosa endobronchitis in rhesus monkeys: II. A histopathologic analysis. J. Med. Primatol.22:257-262,1993.
38. Cheung, A. T. W, Moss, R. B., Leong, A. B. & Novick Jr., W J.: Chronic Pseudomonas aeruginosa endobronchitis in rhesus monkeys: I. Effect of pentoxifylline on neutrophil influx. J. Med. Primatol. 27:357-362,1992.
39. Clarke, L L, Gmbh, B. R., Gabriel, S. E, Smithies, O., Koller, B. H. & Boucher, R. C: Defective epithelial Chloride transport in a gene-targeted mouse model of cystic fibrosis. Science 257-1125-1128,1992.
40. Clerici, M. & Shearer, G. M. : The Thl-Th2 hypothesis of HIV infection: new insights. Immunol. Today. 75: 575581,1994.
41. Cochrane, D. M. G., Brown, M. R. W., Anwar, H., Weller, P.M., Lam, K. & Costerton, J. W: Antibody response to Pseudomonas aeruginosa surface protein antigens in a rat model of chronic lung infection. J. Med. Microbiol. 27:255-261,1988.
42. Collins, F. S.: Cystic fibrosis: molecular and therapeutic implications. Science 256:774-779,1992.
43. Consortium, C.: The Cystic Fibrosis Genetic Consortium: worldwide survey of the AF508 mutation - report from the cystic genetic analysis consortium. Am. J. Hum. Genet. 47:354-359,1990.
44. Conway, S. P.. Simmonds, E. J. & Littlewood, J. M.: Acute severe deterioration in cystic fibrosis associated with influenza A virus infection. Thorax 47: 112-114, 1992.
45. Costerton, J. W, Cheng. K.-J., Geesey, G. G., Ladd, T. L, Nickel, J.C., Dasgtipta, M. & Marrie, T.J.: Bacterial biofilms in nature and disease. In: Ornston L. N., Balows, A. & Baumann, P. (Eds.): Annual review of microbiology. Annual Reviews Inc., Palo Alto 1987, vol. 41, pp. 435-464.
46. Costerton, J. IV, In-in, R.T., & Cheng, K.-J.:Thebacterial glycocalyx in nature and disease. Annual Rev. Microbiol.5J: 299-324,1981.
47. Cripps, A. W, Dunkle)', At. L. & Clancy, R. L.: Mucosal and systemic immunizations with killed Pseudomonas aeniginosa protects against acute respiratory infection in rats. Infect. Immun. 62:1427-1436,1994.
48. Cross, A. S., Sadoff.J. C, Iglewski. B. H. & Sokol, P. A.: Pathogenesis: evidence for the role of toxin A in the pathogenesis of infection with Pseudomonas aeniginosa in human. J. Infect. Dis. 142:538-546,1980.
49. Croire, B. A., Enzersberger, O., Schober-Bendixen, S., Milterer, A., Mundt, W, Livey, I., Pabst, H., Kaeser, R., Eibl, M., Eibl, J. & Dorner, F.: The first clinical trial of mmuno's experimental Pseudomonas aeniginosa flagellar vaccines. In: Homina J. Y, Tanimoto, H., Holder, I. A., Hoiby, N. & Daring, G. (Eds.): Pseudomonas aeniginosa in human disease. Krager, Basel 1991, vol. 44, pp. 143-156.
50. Crystal, R. G., McElvaney, N. G., Roensfeld, M. A., Chu. C.-S., Mastrangeli, A., Hay, J. G., Brody. S. L., Jaffe. H. A., Eissa, N.T. & Danel, C.: Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nature Genetics 8:42-51,1994.
51. Cryz Jr., S. J., Fürer, E., Cross, A. S., Wegmann, A., Germanier, R. & Sadoff, J. C.: Safety and immunogenicity of a Pseudomonas aeniginosa O-polysaccharide toxin A conjugate vaccine in humans. J. Clin. Invest. 80: SI56, 1987.
52. Cryz Jr., S. J., Fürer, E. & Germanier, R.: Protection against Pseudomonas aeniginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide. Infect. Immun. 39:1072-1079,1983.
53. Cryz Jr., S. J., Fürer, K & Que, J. IZ: Synthesis and characterization of a Pseudomonas aeniginosa alginate-toxin A conjugate vaccine. Infect. Immun. 59:45-50, 1991.
54. Cryz Jr., S. J., Fürer, R, Que, J. U, Sadoff.J. C., Brenner, M. & Schaad, U. B.: Clinical evaluation of an octavalent Pseudomonas aeniginosa conjugate vaccine in plasma donors and in bone marrow transplant and cystic fibrosis patients. In: Hoinma J. Y, Tanimoto, H., Holder, I. A., Hoiby, N. & Döring, G. (Eds.):Pseudomonas aeniginosa in human diseases. Krager, Basel 1991, vol. 44, pp. 157-162.
55. Cry: Jr., S.J., Purer, E, Sadoff, J. C. & Germanier, R.: Pseudomonas aeniginosa immunotype 5 polysaccharide-toxin A conjugate vaccine. Infect. Immun. 52:161165,1986.
56. Cryz Jr.. S. J., Sadoff J. C, Cross, A. S. & Fürer, E: Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide toxin A vaccine in humans. In: Hoiby N., Pedersen. S. S., Shand, G. H., Daring, G. & Holder, I. A. (Eds.): Pseudomonas aeruginosainfection. Krager, Basel 1989, vol.42, pp. 177-183.
57. CryzJr., S. J.,Wedgwood, J., Lang, A. B., Ruedeberg, A., Que, J. U., Purer, K & Schaad, U. B.: Immunization of noncolonized cystic fibrosis patients against Pseudomonas aeruginosa. J. Infect. Dis. 169:1159-1162,1994.
58. Cuthbert, A.: Cystic fibrosis gene update. J. Royal Soc. Med. 87:2-4,1994.
59. Danks, D. M., Allan, J. & Anderson, C. M.: Genetic study of fibrocystic disease of the pancreas. Ann. Hum. Genet. 28:323-356,1965.
60. Dasgupta, M. K., Lam, J., Daring, G., Harley, F. L., Zitberbiihlcr. P., Lam, K., Reichert, A., Costerlon, J.W. & Dossetor, J. B.: Prognostic implications of circulating immune complexes and Pseudomonas aeruginosa specific antibodies in cystic fibrosis. J. Clin. Lab. Immunol. 23:25-30,1987.
61. Dasgupta, M. K., Zuberbuhler, P., Abbi, A., Harley, F. L., Brown, N. E, Lam, K., Dossetor, J. B. & Costerton, J. W.: Combined evaluation of circulating immune complexes and antibodies to Pseudomonas aeruginosa as an immunologie profile in relation to pulmonary function in cystic fibrosis. J. Clin. Immunol. 7:51-57,1987.
62. Dean, T. P., Dai, Y, Shuts, J. K., Church, M. K. & Warner, J. O.: Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis. Pediatr. Res. 34:159-161,1993.
63. Deretic, V, Schurr, M. J., Boucher. J. C. & Martin, D. W: Conversion of Pseudomonas aeruginosa to mucoidy in cystic fibrosis: environmental stress and regulation of bacterial virulence by alternative sigma factors. J. Bact. 176:2773-2780,1994.
64. DiSant'Agnese, P.A. & Talamo, R. C.: Pathogenesis and physiopathology of CF of the pancreas. N. Engl. J. Med. 277-1287-1294,1967.
65. Doige, C. A. & Ames, G. F.-L.: ATP-dependent transport systems in bacteria and humans - relevance to cystic fibrosis and multidrug resistance. Annual Rev. Microbiol. 47: 291-319, 1993.
66. Donati. M. A., Haver. K., Gerson, W, Klein, M, McLaughlin, F. J. & Wohl, M. K B.: Long-term alternate day prednisone therapy in cystic fibrosis. Pediatr. Pulmonol. SuppL 5: 111, 1990.
67. Darin, J. R., Dickinson, P., Alton, E. W.F.W., Smith, S. N., Geddes, D. M., Stevenson, B. J., Kimber, W. L., Fleming, S., Clarke, A. R., Hooper, M. L., Anderson, L.,Beddington, R. S. P. & Porteous, D. J.: Cystic fibrosis in the mouse by targeted insertional mutagenesis. Nature 359:211-215,1992.
68. Daring, G., Bellon, G. & Knight, R.: Immunology of cystic fibrosis. In: Hodson M. E. & Geddes, D. M. (Eds.): Cystic fibrosis. Chapman & Hall Medical, London 1995, vol.7, pp. 99-129.
69. Döring, G. & Dauner, H. -M. : Clearance of Pseudomonas aeruginosa in different rat lung models. Am. Rev. Respir. Dis. 138:1249-1253,1988.
70. Daring, G. & Hoiby, N.: Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis. Infect. Immun. 42:197-201,1983.
71. Daring. G., Johansen, H. K., Weidingcr, S. & Hoiby. N.: Allotypes of α1-antitrypsin in patients with cystic fibrosis homozygous and heterozygous for AF508. Pediatr. PuImonoUS: 3-7,1994.
72. Daring. G., Maier, M., Müller, K. Bibi, Z., Tümmler, B. & Kharazmi, A. .'Virulence factors of Pseiidomonas aeruginosa. In: Döring G., Holder, I. A. & Botzenhart, K. (Eds.): Basic research and clinical aspects of Psetidomonas aeruginosa. Karger, Basel 1987, vol. 39, pp. 136-148.
73. Döring, G., Pfeiffer. C., Weber, U., Mohr-Pennert, A. & Dorner, F.: Parenteral application of a Pseiidomonas aeruginosa flagella vaccine elicits specific anti-flagella antibodies in the airways of healthy individuals. Am. J. Respir. Crit. Care Med. 151:983-985,1995.
74. + T cells from orally immunized rats in enhanced clearance of Pseiidomonas aeruginosa from the lung. Immunol. 83: 362-369, 1994.
75. Efthimioii, J., Hudson, M. E, Taylor, P. & Batten, J. C.: Importance of viruses and Legionella pneumophila in respiratory exacerbations of young adults with cystic fibrosis. Thorax 39:150-154,1984.
76. Eigen, H., Rosenstein, B. J., FitzSimmons, S., Schidlow, D.V. & Group, T C. F. F. P. T: A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. 1 Pediatr. 126:515-523,1995.
77. Elborn, J. S., Cordon, S. M. & Shale. D. J.: Host inflammatory responses to first isolation of Pseudomonas aeruginosa from sputum in cystic fibrosis. Pediatr. Pulmonol. 75:287-291,1993.
78. Elson, C. O. & Dertzbaugli. M. T.: Mucosal adjuvants. In: Ogra P. L., Mestecky, J., Lamm, M. K, Sirober, W., McGhee, J. R . & Bienenstock, J. (Eds.): Handbook of mucosal immunology. Academic Press, Inc., San Diego 1994, pp. 391-402.
79. Engelhardt, J. F., Zepeda, M., Colm, J. A., Yankaskas, J. R. & Wilson, J. M.: Expression of the cystic fibrosis gene in adult human lung. J. Clin. Invest. 93: 737-749, 1994.
80. Fanconi, G., Uehlinger, E & Knaiier, C.: Das Coeliakiesyndrom bei angeborener zystischer Pankreas Fibromatose und Bronchiektasien. Wien Med. Wschr. 86: 753-756,1936.
81. ++ levels in the sputum of patients suffering from different respiratory diseases. In: Schöni M. & Kraemer, R. (Eds.): Current problems and new trends in cystic fibrosis. Karger, Basel 1981, vol. 14, pp. 142-145.
82. Fiim, A.: Cytokines and adhesion molecules in acute inflammation. In: David T. J. (Ed.): Recent advances in pediatrics. Churchill Livingstone, Edinburgh 1995, pp. 139-153.
83. Fomsgaard, A.: Antibodies to lipopolysaccharides some diagnostic and protective aspects (thesis). APMIS 98:5-38,1990.
84. Fox. C. W. CambellJr., G. D., Anderson.WM., Zavecz, J. H.. Gilleland, L.B.& GillelandJr., H. E: Preservation of pulmonary function by an outer membrane protein F vaccine. Chest 705:1545-1550,1994.
85. Freihorst, J., Merrick, J. M. & Ogra, P. L: Effect of oral immunization with Pseitdomonas aentginosa on the development of specific antibacterial immunity in the lungs. Infect. Immun. 57:235-238,1989.
86. Furth van, R.: Origin and kinetics of monocytes and macrophages. Sem. Hemathol.7-125-141,1970.
87. Fyfe, J. A. M. & Govan, J. R. W: Alginate synthesis in mucoid Pseitdomonas aeruginosa: a chromosomal locus involved in control. J. Gen. Microbiol. 119: 443450,1980.
88. Gacesa, P. & Russell, N.J.: The structure and properties of alginate. In: Gacesa P. & Russell, N. J. (Eds.): Pseudomonas infection and alginates: Biochemistry, genetics and pathology. Chapman and Hill, London 1990, pp. 29-49.
89. Garner, C. V, D es Jardins, D. & Pier, G. B. : Immunogenic properties of Pseiidomonas aeruginosa mucoid exopolysaccharide. Infect. Immun. 58:1835-1842,1990.
90. George, S. K, Kohan, M. J., Gilmour, M. L, Taylor, M. S., Brooks, H. G., Creason, J. P. & Claxton, L. D.: Pulmonary clearance and inflammatory response in C3H/ HeJ mice after intranasal exposure to Pseudomonas spp. Appl. Environ. Microbiol. 59:3585-3591,1993.
91. Gilleland,H.R, Gilleland,L. B. &Fowler,M.Vaccine efficacies of elastase, exotoxin A, and outer-membrane protein F in preventing chronic pulmonary infection by Pseudomonas aeruginosa in a rat model. J. Med. MicrobioUS: 79-86,1993.
92. Gilleland Jr., H. R, Gilleland, L.B. & Matthews-Greer, J. M.: Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model. Infect. Immun. 56: 1017-1022, 1988.
93. Gilleland Jr., H. R, Parker, M. G., Matthews, J. M. & Berg, R. D.: Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice. Infect. Immun. 44: 49-54, 1984.
94. Goldstein, I. M.: Polymorphonuclear leukocyte lysosomes and tissue injury. Prog. Allergy 20:301-340,1976.
95. Goldstein, W. & Daring, G.: Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis. Am. Rev. Respir. Dis. 134:49-56,1986.
96. Govan, J. R. W & Fyfe, J. A. M.: Mucoid Pseudomonas aeruginosa and cystic fibrosis: resistance of the mucoid form to carbenicillin, flucloxacillin and tobramycin and the isolation of mucoid variants in vitro. J. Antimicrob. Chemother.4:233-240,1978.
97. Govan, J.R.W & Harris, G. S. : Pseudomonas aeruginosa and cystic fibrosis: unusual bacterial adaptation and pathogenesis. Microbiol. Sei. 3:302-308,1986.
98. Graham, L M.. Vasil, A., Vasil, M. L. Voelkel, N. F. & Stenmark, K. R.: Decreased pulmonary vasoreactivity in an animal model of chronic pseudomonas pneumonia. Am. Rev. Respir. Dis. 142:221-229,1990.
99. 4 concentrations and more severe pulmonary disease. J. Allergy Clin. Immunol. 93:100-107,1994.
100. Grinnvood. K., Semple, R. A., Rabin, H. R., Sokol, P. A. & Woods, D. E: Elevated exoenzyme expression by Pseudomonas aeriiginosa is correlated with exacerbations of lung disease in cystic fibrosis. Pediatr. Pulmonol. 15:135-139,1993.
101. Grimwood, K. .To.M., Rabin, H.R. & Woods, D. R : Subinhibitory antibiotics reduce Pseudomonas aeriiginosa tissue injury in the rat lung model. J. Antimicrob. Chemother.2-/: 937-945,1989.
102. Gupta, R. K, Refyveld, E H.,Lindblad, E B., Bizzini. R, Ben-Efraim, S. & Gupta, C. K.: Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 11: 293-306,1993.
103. Hall, S. S.: IL-12 at the crossroads. Science 268:1432-1434,1995.
104. Haren van, E.H.J., Lammers, J.-WJ., Festen, J., Heijerman, H. G. M, Groot, C. A. R. & Hcrwaarden, C. L. A.: The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis. Respir. Med. 89: 209-214,1995.
105. Hart, D. A., Green, R, Whidden, P., Henkin, J. & Woods, D. E: Exogenous rh-urokinase modifies inflammation and Pseudomonas aeriiginosa infection in a rat chronic pulmonary infection model. J. Can. Microbiol. 39: 1127-1134,1993.
106. Hatano, K., Boisot, S., DesJardins, D.. Wright, D. C., Brisker, J. & Pier, G. B.: Immunogenic and antigenic properties of a heptavalent high-molecular-weight Opolysaccharide vaccine derived from Pseudomonas aeriiginosa. Infect. Immun. 62:3608-3616,1994.
107. Hector, R. F., Collins, M. C. & Pennington, J. E:Treatment of experimental Pseudomonas aeriiginosa pneumonia with a human IgM monoclonal antibody. J. Infect. Dis. MO: 483-489,1989.
108. Heinzel, F. P., Sadick, M. D., Holaday, B. J., Coffman, R. L. & Locksley, R. M.: Reciprocal expression of interferon-y or interleukin-4 during the resolution or progression of murine leishmaniasis. J. Exp. Med. 769: 59-72, 1989.
109. Henry, R. L., Mellis, C. M. & Petrovic, L: Mucoid Pseudomonas aeriiginosa is a marker of poor survival in cystic fibrosis. Pediatr. Pulmonol. 12:158-161,1992.
110. Hiller, E. J:\Vas Pseudomonas vaccine really harmful? Abstract, 18th European Cystic Fibrosis Conference, Madrid, Spain, 1993, p.113.
111. Hirakata, Y, Kaku, M., Tomono, K., Tateda, K., Fiiruya. N., Matsumoto, T., Araki, R. & Yamagiichi, K.: Efficacy of erythromycin lactobionate for treating Pseudomonas aeriiginosa bacteremia in mice. Antimicrob. Agents Chemother.56:1198-1203,1992.
112. Hooke, M. A., Sordelli, D. O., Cerquetti, M. C. &Bellanti, J. A.: Differential growth characteristics and immunogenicity of tight and coasting temperature-sensitive mutants of Pseudomonas aeriiginosa. Infect. Immun. 55:99-103,1987.
113. Hornick, D. B. & Fick, R. A.'The immunoglobulin G subclass composition of immune complexes in cystic fibrosis: implications for the pathogenesis of the pseudomonas lung lesion. J. Clin. Invest. 86: 1285-1292,1990.
114. Hornslelh, A., Friis, B., Knudscn, F. U. &Krasilnikoff,R: Hurtigdiagnostik af virusbetingede akutte luflvejsinfektioner. Undersogelser af indlagte born. Ugeskr. La ger 750:1274-1277,1988.
115. Hangen, H. P.: The athymic nude rat. Imtnunological characteristics (thesis). APMIS. 99:1-39,1991.
116. Hubbard, R. C, McElvaney, N. G., Biner, P., Shak, S., Robinson. W.W., Jolley, C, Wu, M., Chernick, M. S. & Crystal R. G. : A preliminary study of aerosolized recombinant human deoxyribonuclease-I in the treatment of cystic fibrosis. N. Engl. J. Med. 326: 812-815, 1992.
117. Hudson,VL.,Wielinski, C.L.&Regelmann,WE:Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years. J. Pediatr. 122:854-860,1993.
118. Hyde. S. C, Gill, D. R., Higgins, C. F., Trezise, A. E O., MacVivish, L J., Cuthbert, A. W, Ratcliff, R., Evans, M. J. & Colledge, W.H. : Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. Nature 362:250-255,1993.
119. Hoiby, N.: Pseudomonasaeruginosa infection in cystic fibrosis. Relationship between mucoid strains of Pseudomonas aeruginosa and the humoral immune response. Acta Pathol. Microbiol. Scand. Sect. R82: 551558,1974.
120. Hoiby, K: Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis (thesis). Acta Pathol. Microbiol. Scand. Suppl.262:3-96,1977.
121. Hoiby, N.: Microbiology of lung infections in cystic fibrosis patients. Acta Paediatr. Scand. Suppl 301:33-54, 1982.
122. Hoiby, N.: Prevention and treatment of infections in cystic fibrosis. Int. J. Antimicrob. Agents. 1: 229-238, 1992.
123. Hoiby, N.: Microbiology of cystic fibrosis. In: Hodson M. E.& Geddes. D. M. (Eds.): Cystic fibrosis. Chapman & Hall Medical, London 1995, vol. 1,75-98.
124. Hoiby, N., Andersen, V & Bendixen, G.: Pseudomonas aeruginosa infection in cystic fibrosis. Humoral and cellular immune responses against Pseudomonas aeruginosa. Acta Pathol. Microbiol. Scand. Sect. C. 83:459-468,1975.
125. Hoiby, N., Daring, G. & Schiotz, P. 01.-The role of immune complexes in the pathogenesis of bacterial infections. Annual Rev. Microbiol. 40:29-53,1986.
126. Hoiby, N., Flensborg, E W, Beck, B.. Friis, B., Jacobsen, S. V. & Jacobsen, L.: Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. Scand. J. Respir. Dis. 58:65-79,1977.
127. Hoiby, N., Giwercman, B., Jensen, E T., Joliansen, II. K., Kroiiborg, G., Pressier, T. & Kharazmi, A.: Immune response in cystic fibrosis - helpful or harmful? In: Escobar H. C, Baquero. F. & Sitarez, L. (Eds.): Clinical eco-logy of cystic fibrosis. Excerpta Medica Elsevier Science Publishers BY., Amsterdam 1993,133-141.
128. Hoiby, N., Giwercman, B., Jensen, E. T., Pedersen, S. S., Koch, C. & Kharazmi, A.: Mechanism of action of antibiotics in chronic pulmonary pseudomonas infection. Adv. Pharmacol. 30:53-84,1994.
129. Incite, H., Massion, P. P., Ueki, I. F., Grattan, K. M., Hara, M., Dohrman, A. F., Chan, B., Lousier, J. A., Golden, J. A. & Nadel, J. A.: Pseudomonas stimulates interleukin-8 mRNA expression selectively in airway epithelium, in gland ducts, and in recruited neutrophils. Am. J. Respir. Cell Mol. Biol. 11:651-663,1994.
130. Iwata. M. & Sato, A.: Morphological and immunohistochemical studies of the lungs and bronchus-associated lymphoid tissue in a rat model of chronic pulmonary infection with Pseudomonas aeruginosa. Infect. Immun.59:1514-1520,1991.
131. Jensen, E. T., Kharazmi, A., Garred, P., Kronborg, G., Fomsgaard, A., Mollnes, T. & Hoiby, N.: Complement activation by Pseudomonas aeruginosa biofilms. Microb. Pathogen. 15:377-388,1993.
132. Jensen, O. M. & Koch, C. : On the effect of A1(OH)3 as an immunological adjuvant. APMIS. 96:257-264,1988.
133. Johansen, H. K., Nir, M., Hoiby, N., Koch, C. & Schwanz, M.: Severity of cystic fibrosis in patients homozygous and heterozygous for AF508 mutation. Lancet 337: 631-634,1991.
134. Johanson Jr.,W.G., Higushi, J. K, Woods, D. K. Gomez. P. & Coalson, J. J.: Dissemination of Pseudomonas aeruginosa during lung infection in hamsters. Am. Rev. Respir. Dis. 132:358-361,1985.
135. Johnson, A. G.: Molecular adjuvants and immunomodulators: new approaches to immunization. Clin. Microbiol. Rev. 7:277-289,1994.
136. Kane, K.: Cystic fibrosis: recent advances in genetics and molecular biology. Annual Clin. Lab. Sei. 18:289296,1988.
137. Karagouni, E E. & Hadjipetroit-Kourounakis, L.: Regulation of isotype immunoglobulin production by adjuvants in vivo. Scand. J. Immunol.31:745-754,1990.
138. Kartner, N., Hanrahan, J. W, Jensen, T. J., Naismith, A. L., Sun, S. Z., Ackerley, C. A., Reyes, E. F., Tsui, L.-C., Rommens, J. M., Bear, C. E. & Riordan, J. R.: Expression of the cystic fibrosis gene in non-epithelial invertebrate cells produces a regulated anion conductance. Cell 64:681-691,1991.
139. Kaufmann, S. H. E: Interleukins, mycobacteria, and listeria. Diagn. Microbiol. Infect. Dis. 13:429-433,1990.
140. Kay, A. B.: Origin of type 2 helper cells. N. Engl. J. Med. 24:567-569,1994.
141. + T-cell response to Leishmania parasites. APMIS. 702:81-88,1994.
142. Kerem, B.-S., Rommens, J. M., Buchanan, J. A.,Markiewicz, D., Cox, T. K., Chakravarli, A., Buchwald, M. & Tsui, L.-C: Identification of the cystic fibrosis gene: gene analysis. Science 245:1073-1080,1989.
143. Kerem, E, Corey, M., Gold, R. & Levison, H.: Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeniginosa. J Pediatr. 116:714-719,1990.
144. Kerein, EL, Corey, M, Kerem, B. S., Rommens, J., Markiemcz, D., Levison, H., Tsui, L.-C. & Durie, P.: The relation between genotype and phenotype in cystic fibrosis - analysis of the most common mutation (AF508). N. Engl. J. Med. 323:1517-1522,1990.
145. Kharazmi, A., Schiotz, P. O., Hoiby. N., Bak, L. & Daring. G.: Demonstration of neutrophil chemotactic activity in the sputum of cystic fibrosis patients with Psendomonas aeniginosa infection. Eur. J. Clin. Invest. 16: 143-148,1986.
146. Kilian, M., Mestecky, J. & Russell, M. W: Defense mechanisms involving Fc-dependent functions of immunoglobulin A and their subversion by bacterial immunoglobulin A proteases. Microbiol. Rev. 52: 296-303, 1988.
147. Kita, K, Sawaki, M., Oku, D., Hamuro, A., Mikasa, K., Konishi, M., Emoto, M., Takeuchi, S., Narita, N. & Kashiba, S.: Suppression of virulence factors of Pseudomonas aeniginosa by erythromycin. J. Antimicrob. Chemother.27- 273-284,1991.
148. Klinger, J. D., Cash H. A., Wood, R. E. & Miler, J. J.:Protective immunization against chronic Pseiidomonas aeniginosa pulmonary infection in rats. Infect. Immun. 39:1377-1384,1983.
149. Knowles, M. R., Church, N. L.Wahner.W.K.Yankaskas, J. R., Gilligan. P.. King, M.. Edwards, L. J., Helms, R. W. & Boucher, R. C.: A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N. Engl. J. Med.322:1189-1194,1990.
150. Knon-les, M. R., Clarke, L. L. & Boucher, R. C.: Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N. Engl. J. Med. 325:533-538,1991.
151. Knowles, M. R., Olivier, K. N., Hohneker. K. W, Robinson, J., Bennett, WD. & Boucher, R. C.: Pharmacologie treatment of abnormal ion transport in the airway epithelium in cystic fibrosis. Chest 707- 71S-76S, 1995.
152. Koch, C. & Hoiby, N.: Pathogenesis of cystic fibrosis. Lancet 341:1065-1069,1993.
153. Koller. D. Y, Götz, M., Eichler, I. & Urbanek, R.:Eosinophilic activation in cystic fibrosis. Thorax 49:496-499, 1994.
154. Konstan, M. W, Byard, P. J., Hoppel, C.L. & Davis, P. B.: Effect of high-dose ibuprofen in patients with cystic fibrosis. N. Engl. J. Med. 332:848-854,1995.
155. Konstan, M. W., Vargo, K. M. & Davis, P. B.: Ibuprofen attenuates the inflammatory response to Pseiidomonas aeniginosa in a rat model of chronic pulmonary infection - implications for antiinflammatory therapy in cystic fibrosis. Am. Rev. Respir. Dis. 141:186-192,1990.
156. Korst, R. J., McElvaney, N. G., Chu. C.-S., Rosenfeld. M. A., Mastrangeli, A., Hay, J., Brody, S. L, Eissa, N. T., Dane], C., Jaffe, H. A. & Crystal, R. G.: Gene therapy for the respiratory manifestations of cystic fibrosis. Am. J. Respir. Crit. Care Med. 757:575-587,1995.
157. Kronborg, G.: Lipopolysaccharide(LPS), LPS-immune complexes and cytokines as inducers of pulmonary in-flammation in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection (thesis). APMIS 705:1-30,1995.
158. Kubesch. P., Dork, T.,Wulbrand, U, Kälin, N., Neumann, T., Wulf, B.. Geerlings, H., Weissbrodt, H., von der Hardt, H. & Tümmler, B. : Genetic determinants of airways' colonisation with Pseudomonas aeruginosa in cystic fibrosis. Lancet 341:189-193,1993.
159. Kurtzhah, J. A. L, Hey, A. S., Jardim, A., Kemp, M., Schaefer, K.-U, Odera, E. O., Clirislensen, C. B. V., Githure, J. l, Olafson, R. W, Theander, T. G. & Kharazmi, A.: Dichotomy of the humanT cell response to Leishmania antigens. II. Absent or Th2-like response to gp63 and Thl-like response to lipophosphoglycan-associated protein in cells from cured visceral leishmaniasis patients. Clin. Exp. Immunol. 96:416-421, 1994.
160. Lamblin, G. & Roussel, P.: Airway mucins and their role in defence against microorganisms. Respir. Med. 87: 421-426,1993.
161. Landsperger, W J.. Kelly-Wintenberg, K. D., Montie, T. C, Knight, L. S., Hansen, M. B., Himtenbiirg, C. C. & Schneidkraut, M. J.: Inhibition of bacterial motility with human antiflagellar monoclonal antibodies attenuates Pseudomonas aeruginosa-inauced pneumonia in the immunocompetent rat. Infect. Immun. 62:48254830,1994.
162. Langford, D.T.& Hiller, J.: A prospective, controlled study of a polyvalent pseudomonas vaccine in patients with cystic fibrosis. In: Adam G. & Valassi-Adam, H. (Eds.): Proceeding, 12th Annual Meeting, European Working Group Cystic Fibrosis, Athens, Greece, 1983, pp. 60-67.
163. Langford, D. T. & Hiller, J.: Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis: three year results. Arch. Dis. Child. 59: 1131-1134,1984.
164. Liebermann, M. M.: Pseudomonas aeruginosa ribosomal vaccine. A comparison of the immunogenicity of vaccines from two different serotypes. In: Hoiby N., Pedersen, S. S., Shand, G. H., Döring. G. & Holder, I. A. (Eds.): Pseudomonas aeruginosa infection. Krager, Basel 1989, voU2, pp. 193-202.
165. Lillehoj, H. S., Lindblad, E. B. & Nichols, M.: Adjuvanticity of dimethyl dioctadecyl ammonium bromide, complete Freund's adjuvant and Corynebacterium parMini with respect to host immune response to coccidial antigens. Avian Dis. 37:731-740,1993.
166. Lindblad, KB.& Spärck, J. V: Basic concepts in the application of immunological adjuvants. Scand. J. Lab. Animal Sei. 14:1-13,1987.
167. Lorian, V. (Ed.): Antibiotics in laboratory medicine. Williams & Wilkins, Baltimore 1986, p. 1085.
168. MacNee, W & Selby, C.: Neutrophil traffic in the lungs: role of haemodynamics, cell adhesion, and deformability. Thorax 48:79-88,1993.
169. Mai, G. T., Seow, W. K., Pier, G. B., McCormack, J. G. & Tlwng, Y. H.: Suppression of lymphocyte and neutrophil functions by Pseudomonas aeruginosa mucoid exopolysaccharide (alginate): reversal by physiochemi-cal, alginase, and specific monoclonal antibody treatments. Infect. Immun. 61:559-564,1993.
170. Makhoul, L R., Merzbach, D., Lichtig, C. & Berant, M.: Antibiotic treatment of experimental Pseudomouas aeruginosa pneumonia in guinea pigs: comparison of aerosol and systemic administration. J. Infect. Dis. 168:1296-1299,1993.
171. Marcus, H., Austria, A. & Baker, N. R.: Adherence of Pseudomonasaeruginosa to tracheal epithelium. Infect. Immun. 57:1050-1053,1989.
172. Markham, R. B., Pier, G. B., Oellner, J. J. & Afizel, S. B.: In vitrot cell-mediated killing of Pseudomonas aeruginosa. II. The role of macrophages and T cell subsets in T cell killing. J. Immunol. 134:4112-4117,1985.
173. Markham, R. B., Pier, G. B. & Powderly, W.G.: Suppressor T cells regulating the cell-mediated immune response to Pseudomonas aeruginosa can be generated by immunization with anti-bacterial T cells. J. Immunol. 141:3975-3979,1988.
174. Martin, D. W, Schurr, M. J., Mudd, M. H., Govan, J. R. W, Holloway, B. W. & Derelic, V.: Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infection in cystic fibrosis patients. Proc. Natl. Acad. Sei. 90: 8377-8381,1993.
175. Me Arthur, H. A. I. & Ceri, H.: Interaction of a rat lung lectin with the exopolysaccharides of Pseudomonas aeruginosa. Infect. Immun. 42:574-578,1983.
176. McElroy, M. C, Pittet, J. R, Wiener-Kronish, J. P. & Dobbs, L. G: A specific alveolar epithelial type I cell marker detects injury to the alveolar epithelial barrier in a model of acute lung injury induced by Pseudomonas aeruginosa. In: Muller B. & Wiehert, P. V. (Eds.): Lung surfactant: Basic research in the pathogenesis of lung disorders. Prog. Respir. Res. Karger, Basel 1994, vol. 27, pp. 165-168.
177. McElvaney, N. G., Doujaiji, B., Moan, M. J., Burnham, M. R., Wu, M. C. & Crystal, R. G.: Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. . Am. Rev. Respir. Dis. 148:1056-1060,1993.
178. McElvaney, N. G., Hubbard, R. C, Biner, P., Chernick, M. S., Caplan, D. B., Frank, M. M. & Crystal, R. G.: Aerosol cd-antitrypsin treatment for cystic fibrosis. Lancet 337:392-394,1991.
179. McElvaney, N. G., Nakamura, H., Biner, P., Herbert, C. A., Wang, W.L., Alphonso, M., Baker, J. B., Catalano, M. A. & Crystal, R. G.: Modulation of airway inflammation in cystic fibrosis: in vivo suppression of interleukin-8 on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. I Clin. Invest. PO: 1296-1301,1992.
180. McGhee, J. R. & Kiyono, H.: New perspectives in vaccine development: mucosal immunity to infections. Infect. Agents Dis. 2:255-273,1993.
181. Meanis, M. B.: Cystic fibrosis: the first 50 years. A review of the clinical problems and their management. In: Dodge J. A., Brock, D. J. H. & Widdicombe, J. H. (Eds.): Cystic fibrosis - current topics. John Wiley & Sons Ltd., 1993, vol. 1, pp. 217-250.
182. Memoranda.: Therapeutic approaches to cystic fibro-sis: memorandum from a joint WHO/ ICF(M)A meeting. BulLWorld Health Org. 72:341-352,1994.
183. Mody, C. R, Buser, D. E, Syme, R. M. & Woods, D. E: Pseudomonas aeriiginosa exoenzyme S induces proliferation of human T lymphocytes. Infect. Immun. 63: 1800-1805, 1995.
184. Morissette, C., Skamene, S. & Gervais, E: Endobronchial inflammation following Pseudomonas aeriiginosa infection in resistant and susceptible strains of mice. Infect. Immun. 63:1718-1724,1995.
185. Mosmann, T. R. & Coffman, R. L.: Thl and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annual Rev. Immunol. 7: 145-173,1989.
186. Moss, R. B.: Antibody production in CFand possibilities for immunotherapy. Pediatr. Pulmonol. Suppl. 6: 66-67,1990.
187. Moss, R. B., Hsu, Y.-P., Lewiston. N. J., Curd, J. G., Milgram, H., Hart, S., Dyer, B. & Larrick, J. W.: Association of systemic immune complexes, complement activation, and antibodies to Pseudomonas aeriiginosa lipopolysaccharide and exotoxin Awith mortality in cystic fibrosis. Am. Rev. Respir. Dis. 133:648-652, 1986.
188. Moss, R. B., Hsu, Y.-P. & Yssel, R: Is CFaTH2 immunoinflammatory disease? Pediatr. Pulmonol. Suppl. 8: 289,1993.
189. Naciicchio, M., Cerquetti. M. C, Meiss, R.P. & Sordelli, D. O.: Role of agar beads in the pathogenicity of Pseudomonas aeriiginosa in the rat respiratory tract. Ped. Res. 18:295-296,1984.
190. Nairn, J. O., Lanzafame, R.J. & Oss van, C. ./.-The adjuvant effect of silicone-gel on antibody formation in rats. Immunol. Invest. 22:151-161,1993.
191. Nakamura. R.YosIiinwra, K., McElvaney, N.G. & Crystal, R. G.: Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J. Clin. Invest. 89:1478-1484,1992.
192. Nelson, J. W, Tredgett, M. W, Sheehan, J. K., Thornton, D. J., Notman, D. & Govan, J. R. IV: Mucinophilicand chemotactic properties of Pseudomonas aeriiginosa in relation to pulmonary colonization in cystic fibrosis. Infect. Immun. 58:1489-1495,1990.
193. Nieto, A., Gay a, A., Jansa, M., Moreno, C. & Vivies, J.: Direct measurement of antibody affinity distribution by hapten-inhibition enzyme immunoassay. Mol. Immunol. 21:537-543,1984.
194. Oislii, K., Sonoda, E, Kobayashi, S., Iwagaki, A.,Nagatake. T., Matsiishima, K. & Matsumoto, K.: Role of interleukin (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect. Immun. 62:4145-4152,1994.
195. Ojeniyi, B. : Polyagglutinable Pseudomonas aeriiginosa from cystic fibrosis patients. A survey (thesis). APMIS 102:1-44,1994.
196. Ong, EL.C, Ellis, M. E.Webb, A. K., Neal, K. R., Dodd, M., Caul, E. O. & Burgess, S.: Infective respiratory exacerbations in young adults with cystic fibrosis: role of viruses and atypical microorganisms. Thorax 44:739742,1989.
197. O'Connor, C. M., Gaffney, K., Keane, J., Southey, A.,Byrne, N., O'Mahoney, S. & Fitzgerald, M A^:al-proteinase inhibitor, elastase activity, and lung disease severity in cystic fibrosis. Am. Rev. Respir. Dis. 148: 1665-1670, 1993.
198. Pamukcii, A., Bush, A. &Bitchdahl, R.: Effects of Psetidomonasaeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr. Pulmonol. 19:10-15,1995.
199. Pedersen, P. S., Flensborg, E W. & Johnsen, S. G.: Urinary 17-ketosteroids in cystic fibrosis. Acta Paediatr. Scand. 70:507-512,1981.
200. Pedersen, S. S.: Lung infection with alginate-producing, mucoid Pseudomonas aeruginosa in cystic fibrosis (thesis). APMIS100:1-79,1992.
201. Pedersen, S. S., Espersen, E, Hoiby, N. & Shand, G. H.: Purification, characterization and immunological cross-reactivity of alginates produced by mucoid Pseudomonas aeruginosa from patients with cystic fibrosis. J. Clin. Microbiol.27- 691-699,1989.
202. Pedersen, S. S., Hoiby, N., Espersen, E & Koch, C: Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax 47:6-13,1992.
203. Pedersen, S. S., Jemen, T., Hoiby, N., Koch, C. & Flensborg, E W: Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients. Acta Paediatr. Scand. 76:955-961,1987.
204. Pedersen, S. S., Kharazmi, A., Espersen, F. & Hoiby, N.: Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response. Infect. Immun. 55:3363-3368,1990.
205. Pedersen, S. S., Shand, G. R, Hansen, B. L. & Hansen, G. N.: Induction of experimental chronic Pseudomonas aeruginosa lung infection with P. aeruginosa entrapped in alginate microspheres. APMIS 98:203-211,1990.
206. Pennington, J. E: Lipopolysaccharide pseudomonas vaccine: efficacy against pulmonary infection with Pseudomonas aeruginosa. J. Infect. Dis. 140:73-80,1979.
207. Pennington, J. E & Ehrie, M. G.: Pathogenesis of Pseudomonas aeruginosa pneumonia during immunosuppression. J. Infect. Dis. 757-764-774,1978.
208. Pennington, J. E, Hickey, W. F., Blackwood, L. L. & Arnaut, M. A.: Active immunization with lipopolysaccharide pseudomonas antigen for chronic pseudomonas bronchopneumonia in guinea pigs. J. Clin. Invest. 68:1140-1148,1981.
209. Pennington, J. E & Menkes, E.:Type-specific vs. crossspecific vaccination for Gram-negative bacterial pneumonia. I Infect. Dis. 144:599-603,1981.
210. Pennington, J.E & Pier, G. B. : Efficacy of cell wall Pseudomonas aeruginosa vaccines for protection against experimental pneumonia. Rev. Infect. Dis. Stippl.5: S852S857,1983.
211. Pennington, J. E, Pier, G. B., Sadoff.J. C. & Small, G. J.: Active and passive immunization strategies for Pseudomonas aeruginosa pneumonia. Rev. Infect. Dis. 8: S426-S433,1986.
212. Pennington, J. E, Reynolds, H. Y., Wood, R. E, Robinson, R. A. & Lcvine, A. S.: Use of Pseudomonas aeruginosa vaccine in patients with acute leukemia and cystic fibrosis. Am. J. Med.58:629-636,1975.
213. Peiersen, N. T.. Hoiby, N.. Mordhorst. C.-H., Lind, K., Flensborg. KW & Brunn, B.: Respiratory infections in cystic fibrosis caused by virus, chlamydia and mycoplasma - possible synergism with Pseudomonas aeruginosa. ActaPaediatr. Scand.70:623-628,1981.
214. Pier, G. B. & Benuett, S. R: Structural analysis and immunogenicity of Pseudomonas aertiginosa imrnunotype 2 high molecular weight polysaccharide. J. Clin. Invest. 77:491-495,1986.
215. Pier, G. B., Des Jardin, D.. Grout, M, Garner, C., Bennett, S. K, Pekoe, G., Fuller. S. A.,Thornton, M. O.. Harkonen, W. S. & Miller, H. C.: Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine. Infect. Immun. 62:3972-3979,1994.
216. Pier, G. B., Des Jardins, D., Aguilar, T., Barnard, M. & Speert, D. P.: Polysaccharide surface antigens expressed by nonmucoid isolates of Pseudomonas aerugi, nosa from cystic fibrosis patients. J. Clin. Microbiol. 24: 189-196,1986.
217. Pier, G. B. & Markham, R. B.: Induction in mice of cellmediated immunity to Pseudomonas aeruginosa by high molecular weight polysaccharide andvinblastine. J. ImmunoU2S: 2121-2125,1982.
218. Pier, G. B., Meluleni, G. & Goldberg, J. B.: Clearance of Pseudomonas aeruginosa from the murine gastrointestinal tract is effectively mediated by O-antigen-specific circulating antibodies. Infect. Immun. 63: 2818-2825, 1995.
219. Pier, G. B., Meluleni, G. & Neuger, E. : A murine model of chronic mucosal colonization by Pseudomonas aeruginosa. Infect. Immun. 60:4768-4776,1992.
220. Pier, G. B., Sounders, J. M., Ames, P., Edwards, M. S., Auerbach, H., Goldfarb, J., Speert, D. P. & Hurwitch, S.: Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older non-colonized patients with cystic fibrosis. N. Engl. J. Med. 577-793-798,1987.
221. Pier, G. B., Small, G. J. & Warren, H. B.: Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections. Science 249:537540,1990.
222. Pittet, J. F, Matthay, M. A., Pier, G. B., Grady, M. & Wiener-Kronish, J.P.: Pseudomonas aeruginosa-mduced lung and pleural injury in sheep. Am. Soc. Clin. Invest. 92:1221-1228,1993.
223. Pollack, M. & Young, L. S.: Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. J. Clin. Invest.65:276-286,1979.
224. Porteous, D. J.: Cystic fibrosis in the mouse and progress towards gene therapy. In: Escobar H., Baquero, F. & Suárez (Eds.): Clinical ecology of cystic fibrosis. Elsevier Science Publishers BY, Amsterdam, 1993, vol. 1034, pp. 27-31.
225. Porteous, D. J.: Current status and future prospects for the treatment of lung disease in cystic fibrosis by gene therapy. Pulm. Pharmacol.7-153-157,1994.
226. Powderly, W.G., Schreiber, J. R., Pier, G. B. & Markham, R. B.: T Cells recognizing polysaccharide-specific B cells function as contrasuppressor cells in the generation of T cell immunity to Pseudomonas aeruginosa. J. Immunol. 140:2746-2752,1988.
227. Power, C, O'Connor, C. M, Mac Farlane, D., O'Mahoney, S., Gaffney, K.. Hay es, J. & Fitzgerald, M. X.: Neutrophil collagenase in sputum from patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 150: 818-822, 1994.
228. Pressler, T., Pedersen, S. S., Espersen, F., Hoiby. N. & Koch, C.: IgG subclass antibody responses to alginate from Pseudomonas aeruginosa in patients with cystic fibrosis and chronic P. aeruginosa infection. Paediatr. Pulmonol. 14:44-51,1992.
229. Ramphal, R., Carnoy, C., Fievre, S., Michalski, J. C., Houdret, N., Lamblin, G., Strecker, G. & Roussel, P.: Pseudomonas aeruginosa recognizes carbohydrate chains containing type 1 (Galbetal-SGlcNAc) or type2 (Galbetal-4GlcNAc) disaccharide units. Infect. Immun. 59:700-704,1991.
230. Ramphal R., Koo, L, Ishimoto, K. S., Totten, P. A., Lam, J. C. & Lory, S.: Adhesion of Pseudomonas aeruginosa pilin-deficient mutants to mucin. Infect. Immun. 59: 1307-1311,1991.
231. Ramsey, B. W. & Smith. A. L: Reduced incidence of respiratory tract infections in cystic fibrosis patients using aerosolized dornase alfa. Dornase Alfa Clin. Series 1:1-5,1994.
232. Rasmussen, J. M.: Inherited deficiencies of complement proteins (thesis). APMIS 99:1-48,1991.
233. Ratdiff.R., Evans, M. J., Cuthbert, A. W, MacVinish, L J., Foster, D., Anderson, J. R. & Colledge, W.H.: Production of a severe cystic fibrosis mutation in mice by gene targeting. Nature Genetics 4:35-41,1993.
234. Regelmann, W.E., Elliott, G. R., Warwick, W.J. & Clawson. C. C.: Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am. Rev. Respir. Dis. 141: 914-921, 1990.
235. Regelmann, WE, Siefferman, C. M., Herron, J. M., Elliot, G. R., Clan-son, C. C. & Gray, B. H.: Sputum peroxidase activity correlates with the severity of lung disease in cystic fibrosis. Pediatr. Pulmonol. 19:1-9,1995.
236. Reimert, C. M., Giwercman, B., Hoiby, N. & Kharazmi, A.: Eosinophil cationic protein in sputum from cystic fibrosis patients with Pseudomonas aeruginosa infections. Lancet 344:1504-1505,1994.
237. Riordan, J. R.: CFTR function. In: Dodge J. A., Brock, D.J.H.& Widdicombe, J. H. (Eds.): Cystic fibrosis - current topics. JohnWiley & Sons Ltd., Chichester 1993, vol. I pp. 157-173.
238. Riordan, J. R., Rommens, J. M., Kerem, B.-S., Ahn, N., Rozmahel, R., Grzelczak, K., Zielenski, J., Lok, S., Plasic, N., Chou, J.-L, Drumm, M. L, lanuzzi, M. C., Collins, F. S. & Tsui, L-C.: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066-1073,1989.
239. Rommens, J. M., lannuzzi, M. C, Kerem, B.-S., Drumm, M. L, Melmer, G., Dean, M., Rozmahel, R., Cole, J. L. Kennedy, D., Ilidaka, N., Zsiga, M., Biichwald, M.,Riordan, J. R., Tsui, L.-C. & Collins, F: Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245:1058-1065,1989.
240. Rook, G. A. W, Hernandez-Pando, R. &Lightman, S. L: Hormones. Peripherally activated prohormones and regulation of theThl/Th2 balance. Immunol. Today. 75:301-303,1994.
241. Rosenstein, B.J. & Flotte, T. R. : New directions in treatment. In: Dodge J. A., Brock, D. J. H. & Widdicombe, J. H. (Eds.): Cystic fibrosis -current topics. John\Viley & Sons Ltd., London 1993, vol. 1, pp. 269-301.
242. Rosenstein, B. J. & Johnson, C. A. C: Longterm followup of phase III rhDNase trial. Pediatr. Pulmonol. Suppl 9:113-114,1994.
243. Salmon, L., Cacalano, G, Gruenert, D. & Prince, A.: Comparison of adherence of Pseudomonas aeruginosa to respiratory epithelial cells from cystic fibrosis patients and healthy subjects. Infect. Immun. 60: 28082814,1992.
244. Schaad, U. B., Lang, A. B., Wedgwood, J., Buehlamnn, U. & Fürer, K: Serotype-specific serum IgG antibodies to lipopolysaccharides of Pseudomonas aeruginosa in cystic fibrosis - correlation to disease, subclass distribution, and experimental protective capacity. Paediatr. Res. 27-508-513,1990.
245. Schaad, U. B., Lang, A. B., Wedgwood, J., Ruedeberg, A., Que, J. U., Fürer, E. & Cryz Jr., S. J.: Safety and Immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis. Lancet 338:1236-1237,1991.
246. Schiotz, P. O.: Local humoral immunity and immune reactions in the lungs of patients with cystic fibrosis (thesis). Acta Paediatr. Scand. Suppl. 276:3-25,1981.
247. Schmiegelow, K., Eiberg. H., Tsui, L.-C, Buchwald, M., Phelan, P. D., Williamson. R., Warwick, W, Niebuhr, K, Mohr, J., Schwartz, M. & Koch, C.: Linkage between the loci for cystic fibrosis and paraoxonase. Clin. Gen. 29:374-377,1986.
248. Schwartz, M., Johansen, K K., Koch, C. & Brandt, N. J.: Frequency of the AF508 mutation on cystic fibrosis chromosomes in Denmark. Hum. Genet. 85: 427-428, 1990.
249. Shak, S.: Aerosolized recombinant human DNase I for the treatment of cystic fibrosis. Chest 107: S65-S70, 1995.
250. Shale, D. J. : Viral infections: a role in the lung disease of cystic fibrosis. Thorax 47:69,1992.
251. 4 production by leukocytes in patients with cystic fibrosis. Prostaglandins, Leukotrienes and Essential Fatty Acids. 51:407-410,1994.
252. Smith, R. L.,Wysocki, J. A., Brunn, J. N., De CourcyJr., S. J.. Blakemore.W S. & Mudd, S.: Efficacy of ribosomal preparations from Pseudomonas aeruginosa to protect against intravenous Pseudomonas challenge in mice. J Reticuloendothel. Soc.7J: 22-30,1974.
253. Snapper, C. M.&Paul.WR.-Interfreron-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236:944-947,1987.
254. Sordelli, D. O., Cerquetti, M. C, Bellanti. J.A. & Hooke, A. M.: Specific pulmonary defences against Pseudomonas aeriiginosa after local immunization with temperature-sensitive mutants. J. Gen. Microbiol. 133: 2835-2841,1987.
255. Sordelli, D. O., Cerquetti, M. C., El-Taml, G., Ramwell, P. W, Hooke, A. M. & Bellanti, J. A.: Ibuprofen modifies the inflammatory response of the murine lung to Pseudomonas aeriiginosa. Eur. J. Respir. Dis. 67: 118-127, 1985.
256. Sordelli, D. O., Cerquetti, M. C, Fontán, P. A. & Meiss, R. P.: Piroxicam treatment protects mice from lethal pulmonary challenge with Pseitdomonas aeriiginosa. I Infect. Dis. 759:232-238,1989.
257. Sordelli, D. O., Cerquetti, M. C. & Hooke, A. M.: Replication rate of Pseudomonas aeriiginosa in the murine lung. Infect. Immun. 50:388-391,1985.
258. Sordelli, D. O., Cerquetti, M. C., Hooke, A. M. & Bellanti, J. A.: Enhancement of Pseudomonas aeriiginosa lung clearance after local immunization with a temperature-sensitive mutant. Infect. Immun. 39: 1275-1279, 1983.
259. Sordelli, D. O., Djafari, M., García, V.K, Fontán, P.A. & Daring, G.: Age-dependent pulmonary clearance of Pseudomonas aeriiginosa in a mouse model: diminished migration of polymorphonuclear leukocytes to N-formyl-methionyl-leucyl-phenylalanine. Infect. Immun. 60:1724-1727,1992.
260. Sordelli, D. O., Maori, C. N., Maillie, A.J. & Cerquetti, M. C. : A preliminary study on the effect of anti-inflammatory treatment in cystic fibrosis patients with Pseudomonas aeriiginosa lung infection. Int. J. Immunopathol. Pharmacol.7-109-117,1994.
261. Sordelli, D. O., Zeligs, B. J., Cerquetti, M. C, Hooke, A. M. & Bellanti, J. A. : Inflammatory responses to Pseudomonas aeriiginosa and Staphylococciis aureiis in the murine lung. Eur. J. Respir. Dis. 66:31-39,1985.
262. Sorenscn, R. U. & Klinger, J. D.: Biological effects of Pseudomonas aeruginosa phenazine pigments. In: Daring G., Holder, I.A. & Botzenhart, K. (Eds.): Basic research and clinical aspects of Pseudomonas aeriiginosa. Krager, 1987, vol. 39, pp. 113-124.
263. Sorensen, R. U., Stern, R. C., Chase, P. A. & Palmar, S. H.: Changes in lymphocyte reactivity to Pseudomonas aeriiginosa in hospitalized patients with cystic fibrosis. Am. Rev. Respir. Dis. 725:37-41,1981.
264. Southern Jr., P.M., Pierce, A. K. & Sanford, J. P.: Comparison of the pulmonary bactericidal capacity of mice and rats against strains of Pseudomonas aeruginosa. Appl. Microbiol. 21:377-378,1971.
265. Starke, J. R., Edwards, M. S., Langston, C. & Baker, C J.: A mouse model of chronic pulmonary infection with Pseudomonas aeruginosa and Pseudomonas cepacia. Pediatr. Res. 22:698-702,1987.
266. Stevenson, M. M., Kondratieva, T.K., Apt. A. S.. Tarn, M. F. & Skamene, E. : In vitro and in vivo T cell responses in mice during bronchopulmonary infection with mucoid Pseudomonas aeruginosa. Clin. Exp. Immunol. 99:98-105, 1995.
267. Stirer, H. G., Zacliidniak, K. & Speert, D. R: Inhibition of polymorphonuclear leukocyte chemotaxis by the mucoid exopolysaccharide of Pseitdomonas aeruginosa. Clin. Invest. Med. 11: 247-252,1988.
268. Suter, S.: The role of bacterial proteases in the pathogenesis of cystic fibrosis. Am. J. Respir. Crit. Care Med. 750:8118-8122,1994.
269. Suter, S., Schaad, U. B., Morgenthaler, J. J., Chevalier, I. & Schnebli, H.-R: Fibronectin-cleaving activity in bronchial secretions of patients with cystic fibrosis. J. Infect. Dis. 158:89-100,1988.
270. Suter, S., Schaad, U. B., Roux. L.. Nydegger. U. K & Waldvogel, F. A.: Granulocyte neutral proteases and Pseudomonas elastase as possible causes of airway damage in patients with cystic fibrosis. J. Infect. Dis. y.-523-531,1984.
271. Suter, S., Schaad, U. B., Roux-Lombard, P., Girardin, K, Grau, G. & Dayer, J.-M.: Relation between tumour necrosis factor-ot and granulocyte elastase-cc 1-proteinase inhibitor complexes in the plasma of patients with cyst, ic fibrosis. Am. Rev. Respir. Dis. 140:1640-1644,1989.
272. Szaff, M., Hoiby, N. & Flensborg, K W: Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr. Scand. 72:651-657,1983.
273. Tanaka, EL, Kanthakumar, K., Cundell. D. R., Tsang, K. W.T., Taylor, G. W,Kuze, F., Cole, P.J. & Wilson, R..-The effect of erythromycin on Pseudomonas aeruginosa and neutrophil mediated epithelial damage. J. Antimicrob. Chemother.33:765-775,1994.
274. Tanaka, K, Yuba, Y, Sato, A. & Kuze, E: Effects of the beige mutation on respiratory tract infection with Pseudomonas aeruginosa in mice. Exp. Lung Res. 20: 351-366,1994.
275. Taylor, C. R: Cytokines as adjuvants for vaccines: antigen-specific responses differ from polyclonal responses. Infect. Immun. 63:3241-3244,1995.
276. Tegtmeier, B. R. & Andersen, B. R. : Mechanisms of lipopolysaccharide-induced protection against Pseudomonas sepsis in granulocytopenic mice. Rev. Infect. Dis. Suppl.5: S963-S970,1983.
277. Thomassen, M. J., Klinger, J. D.. Winnie, G. B., Wood, R. K, Buriner, C.,Tomashefski, J. F., Horomtz, J. G. & Tandler, B.: Pulmonary cellular response to chronic irritation and chronic Pseudomonas aeruginosa pneumonia in cats. Infect. Immun. 45:741-747,1984.
278. Tost, M. F., Zakem, H. & Berger, M. : Neutrophil elastase cleaves C3bi on opsonized Pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J. Clin. Invest. 86: 300-308,1990.
279. Tosi, M. F, Zakcm-Cloud, H., Demko, C. A., Schreiber, J. R., Stern, R. C, Konstan, M. W & Berger, M.: Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection. Infect. Immun. 772:453-461,1995.
280. Tsui, L.-C: The cystic fibrosis genotype-phenotype consortium: worldwide survey of the ΔF508 mutation. IV Latin American Cystic Fibrosis Congress, San José, Costa Rica, August 3-61994, p.l.
281. Valerius, N. H.: Chemotaxis of neutrophil granulocytes; measurement, cell biology and clinical significance (thesis). Lægeforen. ForIag7-24 1984.
282. Valerius. N. H.. Koch, C. & Hoiby, N.: Prevention of chronic Pseudomonasaeruginosa colonisation in cystic fibrosis by early treatment. Lancet 338:725-726, 1991.
283. Valmori, D., Romero, J. F., Men, Y, Maryanski, J.L.Romero, P. & Corradin, G: Induction of a cytotoxicT cell response by co-injection of aT helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (I FA): further enhancement by preinjection of IFA alone. Eur. J. Immunol.24: 1458-1462,1994.
284. Vuopio-Varkila, J., Nurminen, M., Pyhälä, L. & Mäkela, P. H.: Lipopolysaccharide-induced non-specific resistance to systemic Escherichia coli infection in mice. J. Med. Microbiol.25:197-203,1988.
285. Waine, G. J.: Nucleic acid vaccines. Parasitol.Today.10: 453-454,1994.
286. Waine, G. J. & McManus, D. P.: Nucleic acids: vaccine of the future. Parasitol. Today. 11:113-116,1995.
287. Wang, K L., Prober, C. G., Manson, B., Corey, M. & Le\ison. H.: Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N. Engl. J. Med. 311:1653-1658,1984.
288. Welsh M.J. & Smith, A. E: Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73:1251-1254,1993.
289. Wiener-Kronish, J. P., Sakuma, T., Kudoh, I., Pittet, J.-E, Frank, D., Dobbs, L, Vasil, M.L. & Matthay, M. A.: Alveolar epithelial injury and pleural empyema in acute aeruginosa pneumonia in anaesthetized rabbits. J. Appl. Physiol. 75:1661-1669,1993.
290. Wilson, J. M.: Cystic fibrosis - vehicles for gene therapy. Nature 565:691-692,1993.
291. Wine, J. J.: Basic aspects of cystic fibrosis. Clin. Rev. Allergy. 9:1-28,1991.
292. Winnie, G R, Cowan, R. G & Wade, N. A.: Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis. J. Pediatr. 114:309-314,1989.
293. Winnie, G. B., Klinger, J. D., Sherman. J. M. & Tlwmassen, M. J.: Induction of phagocytic inhibitory activity in cats with chronic Pseudomonas aeruginosa pulmonary infection. Infect. Immun. 38:1088-1093,1982.
294. Wisnieski, J. J., Todd, E. W, Fuller, R., Jones, P. K., Dearborn, D. G., Boat, T.F. & Naff, G. B. : Immune complexes and complement abnormalities in patients with cystic fibrosis. Am. Rev. Respir. Dis. 752:770-776,1985.
295. Wood, R. E : Treatment of CF lung disease in the first two years. Pediatr Pulmonol. Suppl. 4:68-70,1989.
296. Wood, R. E, Boat, T.F. & Doershuk, C. F.: Cystic fibrosis. Am. Rev. Respir. Dis. 775:833-878,1976.
297. Wood, R. E, Pennington, J. E & Reynolds, H. Y.: Intranasal administration of a Pseudomonas lipopolysaccharide vaccine in cystic fibrosis patients. Pediatr. Infect. Dis. 2:367-369,1983.
298. Woods, D.E & Bryan. L. E: Studies on the ability of alginate to act as a protective immunogen against in-fection with Pseudomonas aeruginosa in animals. J. Infect. Dis. 151:581-588,1985.
299. Woods, D. K, CryzJr, S. J.. Friedman, R. L. & Iglewski, B. H. : Contribution of toxin A and elastase to virulence of Pseudomonas aeruginosa in chronic lung infections of rats. Infect. Immun. 36:1223-1228,1982.
300. Woods. D. K, Sokol, P. A., Bryan, L. K, Storey, D. G, Mattingly, S. J., Vogel, H.J. & Ceri, H.: In vivo regulation of virulence in Pseudomonas aeruginosa associated with genetic rearrangement. J. Infect. Dis. 163:143-149, 1991.
301. Woods, D. K, Straits, D. C, Johanson Jr., W.G. & Bass, J. A.: Role of fibronectin in the prevention of adherence of Pseudomonas aeruginosa to buccal cells. J. Infect. Dis. 143: 784-790, 1981.
302. Woods, D. E, Straits, D. C, Johanson Jr., W.G. & Bass, J. A.: Factors influencing the adherence of Pseudomonas aeruginosa to mammalian buccal epithelial cells. Rev. Infect. Dis. 5 Suppl.: S846-S851,1983.
303. Woods, D. E., Straits, D. C, Johanson Jr., W. G., Berry, V. K. & Bass, J. A. : Role of pili in adherence of Pseudomonas aeruginosa to mammalian buccal epithelial cells. Infect. Immun. 29:1146-1151,1980.
304. Wretlind, B.: Studies on the role of proteases in the pathogenicity of Pseudomonas aeruginosa (thesis). Karolinska Instituttet pp. 1-37,1977.
305. Wye, J. E. V., Collins, M. S.. Baylor, At.. Pennington, J. R, Hstt, Y.-P., Sampamejsopa, V. & Moss, R. B.:Pseudomo-nas hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis. Pediatr. Pulmonol.9:7-18,1990.
306. Yamaguchi. T. & Yamada, H..'Role of mechanical injury on airway surface in the pathogenesis of Pseudomonas aeruginosa. Am. Rev. Respir. Dis. 144:1147-1152,1991.
307. Yamalnira, M., Uyemura, K., Deans, R. J.,Weinberg. K., Rea, T. H., Bloom. B. R. & Modlin, R. L: Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 254:277-279,1991.
308. Yokoiyama, S. & Fujiwana, K.: Effects of antibiotics on Tysser's disease. Jpn. J. Exp. Med. 41:49-57,1971.
309. Young, L. S. & Armstrong. D.: Human immunity to Pseudomonas aeruginosa. I. In vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors. J. Infect. Dis. 725:257-276,1972.
310. Yu, L, Lee, K. K., Hodges, R. S., Paranchync, W & Irvin. R. T.: Adherence of Pseudomonas aeruginosa and Candida albicans to glycosphingolipid (Asialo-GMl) receptors is achieved by a conserved receptor-binding domain present on their adhesins. Infect. Immun. 62: 5213-5219,1994.
311. Zabner, J., Couture, L. A., Gregory, R. J., Graham, S. M., Smith, A.K & Welsh, M. J.: Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 75:207-216,1993.